GCM
EBS icon

Gladius Capital Management’s Emergent Biosolutions EBS Stock Holding History

Gladius Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,492
Closed -$18.3K – 397
2023
Q2 		$18.3K Sell
2,492
-217
-8% -$2.01K ﹤0.01% 309
2023
Q1 		$28.1K Sell
2,709
-404
-13% -$4.88K ﹤0.01% 298
2022
Q4 		$36.8K Buy
3,113
+1,531
+97% +$23.7K ﹤0.01% 250
2022
Q3 		$34K Buy
+1,582
New +$44K ﹤0.01% 270

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Gladius Capital Management's EBS Position: Q3 2023 in Review

Gladius Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 2,492 shares — an estimated $18.3K sold.

Gladius Capital Management first reported a position in EBS in Q3 2022 and held it in 4 quarters. The position peaked at $36.8K in Q4 2022. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • Gladius Capital Management reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 2,492 Emergent Biosolutions shares in Q3 2023, an estimated $18.3K.
  • Gladius Capital Management first reported a position in Emergent Biosolutions in Q3 2022 and held it in 4 quarters.
  • Gladius Capital Management's Emergent Biosolutions position peaked at $36.8K in Q4 2022.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.